Brind.
  1. Ipsen contributed royalties to Exelixis's collaboration revenues following the launch of CABOMETYX for NETs.

Cabometyx drove strong financial results for Exelixis in July 2025.

2 reports, 1 independent Updated Jul 20
Gone quiet
Reports
2
Developments
2
Repetition
0%

New informationRepeats or wire copies

AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.

What happened

Some supportReported by 1 outlet

Cabometyx drove strong financial results for Exelixis in July 2025.

Who's involved

What this event is mainly about
Exelixis

How it developed

Newest first. Tap a step to see who reported it.
  1. Cabometyx generated strong financial results for Exelixis.1 source
  2. Stephens upgraded Exelixis stock, citing strong financials and increased FDA approval probability for zanzalintinib.

Keep exploring

Part of

Ipsen contributed royalties to Exelixis's collaboration revenues following the launch of CABOMETYX for NETs. All 1 developments

The entities involved

  • Exelixis

    American biotechnology company

    Nothing else this week.

Related events

Coverage

Newest first; wire copies grouped
  • Motley FoolHere's Why This $50 Healthcare Stock Could Be the Next $200 Winner Exelixis' most important product should continue driving strong financial results through the end of the decade. The oncology specia
  • Unknown outlet